Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [1] SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
    Gurgle, Holly E.
    White, Karen
    McAdam-Marx, Carrie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 239 - 249
  • [2] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [3] Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer, Milton
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (05) : 461 - 463
  • [4] GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
    Neves, Joao Sergio
    Borges-Canha, Marta
    Vasques-Novoa, Francisco
    Green, Jennifer B.
    Leiter, Lawrence A.
    Granger, Christopher B.
    Carvalho, Davide
    Leite-Moreira, Adelino
    Hernandez, Adrian F.
    Del Prato, Stefano
    McMurray, John J. V.
    Md, Joao Pedro Ferreira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 517 - 525
  • [5] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [6] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Goncalves, Edison
    Bell, David S. H.
    DIABETES THERAPY, 2018, 9 (03) : 919 - 926
  • [7] GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
    Karagiannis, Thomas
    Tsapas, Apostolos
    Athanasiadou, Eleni
    Avgerinos, Ioannis
    Liakos, Aris
    Matthews, David R.
    Bekiari, Eleni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 174
  • [8] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [9] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    LANCET, 2021, 398 (10296) : 262 - 276
  • [10] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
12345